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The Association of D-Dimer Levels with Other
Prognostic Factors in Patients with Lung Cancer
Aim: To determine the factors related with coagulation disorders, deep venous thrombosis and
thromboembolic events that are significant causes of morbidity and mortality in patients with lung cancer.
Materials and Methods: D-dimer (DD) levels at the time of diagnosis were determined in patients diagnosed
with lung cancer and these cases were monitored prospectively for thromboembolic events and survival.
Results: DD levels significantly increased and were associated with length of survival in lung cancer patients.
Age, histopathological type, extent of the disease (stage), DD, performance status (ECOG), and
thromboembolism were found to effect survival. DD, thromboembolism, ECOG, and histopathological type
were found to be independent risk factors.
Conclusions: Survival time is significantly shorter in the cases with thromboembolism. DD levels can be
monitored and thromboembolism can be investigated when high DD levels are detected. Mortality and
morbidity can significantly be reduced through initiation of anticoagulant treatment (low molecular weight
heparin and warfarin) in the early period. DD can be considered as an inexpensive, simple test to be used in
the diagnosis, treatment, and follow-up process of lung cancer patients.
Key Words: D-dimer, lung cancer

Akci¤er Kanserli Hastalar›n D-Dimer Düzeylerinin Di¤er Prognostik Faktörler
ile Olan ‹liﬂkisi
Amaç: Akci¤er kanserli hastalarda önemli bir morbidite ve mortalite nedeni olan koagülasyon bozukluklar›,
derin ven trombozlar› ve tromboembolik olaylar ile iliﬂkili faktörlerin belirlenmesi ve prognozla iliﬂkilerinin
saptanmas›d›r.
Yöntem ve Gereç: Akci¤er kanserli olgular›n tan› an›ndaki koagülasyon faktörlerinin belirlenmesi, olgular›n
prospektif olarak izlenerek geliﬂen tromboembolik olaylar›n saptanmas› ve hastalar›n sa¤kal›mlar›n›n
belirlenmesidir.
Bulgular: Akci¤er kanserli olgularda D-dimer (DD) düzeylerinde belirgin yükseklik saptanm›ﬂ ve sa¤kal›m ile
iliﬂkili bulunmuﬂtur. Yaﬂ, histopatolojik tip, hastal›¤›n yayg›nl›¤› (evre), DD, performans durumu (ECOG),
tromboemboli, sa¤kal›m üzerine etkili de¤iﬂkenler olarak saptanm›ﬂt›r. Bunlardan DD, tromboemboli geliﬂimi,
ECOG ve histopatolojik tip ba¤›ms›z risk faktörü olarak belirlenmiﬂtir.
Sonuç: Tromboemboli saptanan olgularda sa¤kal›m önemli derecede k›sad›r. DD düzeyleri takip edilerek
yükseklik tespit edildi¤inde tromboemboli aç›s›ndan araﬂt›r›labilir. Erken dönemde antikoagülan tedavi (düﬂük
moleküler a¤›rl›kl› heparin ve warfarin) uygulanmas›yla mortalite ve morbidite önemli derecede azalt›labilir. DD
akci¤er kanserli hastalar›n tan›, tedavi ve takip aﬂamas›nda kullan›labilecek ucuz, kullan›m› kolay bir test olarak
de¤erlendirilmiﬂtir.
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Coagulation or fibrinolytic system activation is present in lung cancer patients at
clinical or subclinical level. There is a complex interaction, which has an important role
in the course of the disease, between pathogenetic mechanisms of thrombosis, tumor
cells, homeostatic systems, and patient characteristics. Patients with deep venous
thrombosis (DVT) or subclinical hypercoagulopathy usually have worse prognosis.
Activation of the coagulation system not only plays a role in the local and systemic
dissemination of the disease, but also has a significant impact on mortality and survival
rate by leading to thromboembolic events (1).
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Determination of coagulation and fibrinolytic system
markers may be important in the evaluation of their
relationship with disease stage, performance status of the
patients, and survival as well as in the selection of
treatment that will be administered to the patient.
Currently, similar treatment methods are used in several
subgroups of lung cancer patients. Although these
treatment methods can provide substantial benefits for
survival and quality of life in early stages, these benefits
become significantly less in later stages. When adverse
event profile and costs and benefits of these treatment
alternatives are evaluated, there appears a need for
different treatment regimes in some patients.
Measurement of DD levels can be performed by
inexpensive and simple methods in most health-care
institutions. Fibrin, which is degraded by activated
plasmin following the activation of the fibrinolytic system,
is the main ingredient in thrombus. Fibrin degradation
products including DD are formed by the degradation of
cross-linked fibrin. It is formed in all conditions where
coagulation and fibrinolytic systems are activated. It is
known to be increased in certain medical conditions such
as pulmonary embolism, DVT, solid tumors, leukemias,
chronic liver diseases, serious infections, trauma, recent
surgery, disseminated intravascular coagulation (DIC),
pregnancy, preeclampsia, vasculitis, sickle-cell anemia,
myocardial infarction, and unstable angina pectoris
(2,3,4,5).
Plasma concentration of DD is increased either due to
increased production or decreased excretion (6). Since
2% to 3% of plasma fibrinogen is transformed into fibrin
in healthy individuals, very low amount of DD can be
detected in plasma (7). Its half-life is about 8 h, and its
clearance from the plasma is accomplished via the urinary
and the reticuloendothelial system. In contrast to other
markers of homeostasis, DD is a relatively more
convenient and more stable marker to measure, thus can
be utilized in routine clinical practice as well as in
epidemiologic studies. It can be detected in blood and
plasma using specific monoclonal antibodies that are
developed against epitopes located on DD. Despite being
a fibrinogen degradation product, DD also increases
plasma fibrinogen levels by increasing its hepatic
synthesis (8).
Coagulation and fibrinolytic systems have previously
been investigated in lung cancer patients, and correlations
between D-dimer (DD) levels and several variables such as
210
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tumor stage and types have been demonstrated (2,9).
Goal of this study is to determine the high risk patient
groups and implement early treatment interventions.
More aggressive treatment methods can be utilized in
patients with early stage disease when there is evidence
of hypercoagulation. Palliative treatment alternatives may
be considered instead of chemotherapy in late stage
disease, thus reducing drug-related costs and increasing
quality of life in these patients.
D-dimer, being a simple and inexpensive test, can be
preferred as a screening tool. Other treatment
alternatives such as heparin, low molecular weight
heparin, and warfarin can be initiated in those patients,
who do not have any contraindications, in an earlier
period including the time interval before confirmation of
histopathological diagnosis.

Materials and Methods
Information about the study was provided to all
patients (and/or their families) with a confirmed
histopathological diagnosis of lung cancer and those who
gave informed consent were included in the study.
Follow-up forms were prepared for each patient.
A total of 70 patients (65 men, 5 women) were
included. Their mean age was 62.4 ± 10.9 years and
median age was 63.0 ± 10.97 (Range: 21-83) years.
Demographic information, physical examination findings,
biochemical laboratory test results, imaging studies
including thoracic, abdominal and cranial computerized
tomography and bone scintigraphy, bronchoscopy
findings and histopathological evaluation results of
biopsy, BAL (bronchoalveolar lavage) and sputum
material were recorded on follow-up forms.
Two whole blood samples of 5 ml each were obtained
from every patient and plasma and serum were separated
and stored at -80 °C. At the end of 3-year follow-up
period, laboratory measurements, which are explained
below, were performed on plasma and serum samples.
Date of histopathological diagnosis was recorded as
the time of diagnosis in all patients and they were
followed up in 2-month intervals through their oncology
follow-up cards and addresses to record their exact date
of death.
Staging of lung cancer was performed according to
systems introduced by WHO/IASLC (World Health
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Organization/International Association for Study of Lung
Cancer) in 1999 and by “American Joint Committee on
Cancer” and “Union Internationale Contre le Cancer” in
1997. Performance status was evaluated by ECOG
(Eastern Cooperative Oncology Group) score.
Inclusion criteria
Patients who are recently diagnosed with lung cancer
(in last year), patients who are not on regular
anticoagulant or antiaggregant treatment (patients using
acetyl salicylate not exceeding a dose of 75 mg/week
were included in the study), patients who do not have a
personal or family history of thrombophilia, patients who
do not have a previous history of chemotherapy,
radiotherapy or surgery due to malignancy, patients in
any stages of lung cancer, patients with ECOG scores of
1-2-3.
Exclusion criteria
Patients who do not provide consent to be included in
the study or those who withdraw their consent at any
stage of the study, patients with ECOG score of 4,
patients who are on regular anticoagulant and
antiaggregant treatment, patients with a family history of
coagulopathy, patients with a previous history of
thromboembolism, patients with inadequate follow-up
data.
Laboratory Measurements
D-dimer (DD) was measured by enzyme-linked
immunosorbent assay (ELISA) method using IMUCLONE
D-dimer ELISA kit (American Diagnostica Inc. - Cat. No
602). Specific monoclonal antibodies that bind to
epitopes located on DD are utilized in nearly all laboratory
methods measuring DD levels. These epitopes are not
found on fibrin, fibrinogen, and non-cross-linked fibrin.
Although many techniques can be used in DD
measurement, ELISA is considered as the “gold standard”.
ELISA method has a high sensitivity for DD (greater than
99%) and can detect DD concentrations of as low as 3080 ng/dl.
Statistical Analysis
Data were recorded using Microsoft Excel program.
Statistical analysis was performed using SPSS/PC version
10.0. Survival means of the study groups were computed
by Kaplan-Meier analysis. Survival time was assessed in
months. Subgroup comparisons were made by log rank
method. P values of less than 0.05 were considered
statistically significant.
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Relationships between factors that may have effects
on prognosis were assessed by Cox regression analysis. P
values of less than 0.05 in Cox regression analysis were
considered statistically significant.
Kruskal-Walls test was used in multiple comparisons
of the groups. Mann Whitney U-test and t-test were used
in between-group comparisons. Pearson and Spearman
correlation analyses were also performed to assess
associations between study variables.

Results
A total of 70 patients consisting of 5 women (7.1%)
and 65 men (92.9%) were followed up for 12 to 28
months throughout the study period. Five men were alive
at the end of the study, and 65 patients were deceased.
Mean age of the patients with small cell lung cancer
(SCLC) (all were in extensive stage) was 52 ± 9.8 years.
There was a 22-year-old Stage IB case among non-small
cell lung cancer (NSCLC) patients. Mean age was 64 ± 1.4
(Range: 33-65) years in Stage II cases (n = 2), 52 ± 9.1
(Range: 44-62) years in Stage IIIA cases (n = 3), 64.9 ±
8.1 (52-80) years in Stage IIIB cases (n = 24), and 62.7
± 10.6 (43-83) years in Stage IV cases (n = 40). Clinical
characteristics of the patients are summarized in Table 1.
Table 1. Clinical characteristics of the patients.
Characteristic

Sex (Female/Male)
Histopathology
SCLC
SqCLC
NSCLC-U
Adenocarcinoma
ULC
ECOG
1
2
3
Treatment
Chemotherapy (N/Y)
Radiotherapy (N/Y)
Surgery (N/Y)
Thromboembolic event

Number of
patients

%

5/65

7.1/92.9

7
16
14
30
2

10
22.9
20
42.9
2.9

8
46
16

11.4
65.7
22.9

2/68
36/34
63/7
7

3/97
51/49
90/10
10

Abbreviations: SCLC: Small Cell Lung Cancer, NSCLC-U: Non-Small Cell
Lung Cancer-undifferentiated, SqCLC: Squamous Cell Lung Cancer, ULC:
Undifferentiated Lung Cancer, N: No, Y: Yes
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All SCLC cases were in extensive stage (10% of the
study population). Thirty patients with NSCLC were in
Stage IV (47.1%), 24 (34.3%) were in Stage IIIB, 3
(4.3%) were in Stage IIIA, 2 (2.9%) were in Stage II, and
1 (1.4%) was in Stage I (Table 2).

Mean survival time was 11.47 ± 1.1 and 9.47 ± 1.99
months in men and women, respectively. Median survival
time was 11.77 ± 1.82 and 9.40 ± 3.65 months in men
and women, respectively. Sex did not have any
statistically significant effect on survival ( P > 0.05).
Mean survival time was 1.75 ± 0.33 months and median
survival time was 1.77 ± 0.4 months in SCLC. Mean
survival time was 11.17 ± 1.01 months and median
survival time was 11.77 ± 1.18 months in NSCLC. There
was a statistically significant difference between SCLC and
NSCLC in terms of survival time ( P < 0.001) (Figure 1).

In NSCLC cases, while survival was significantly
different in Stage IIIA compared to Stage IIIB ( P <
0.001) and Stage IV ( P < 0.05), no significant difference
was found between late Stage IV and IIIB (log Rank =
0.187, P > 1.74). Statistical comparison could not be
performed between Stage I and II patients and other
groups due to very few numbers of cases (Figure 2).

One-year survival rates were 0% for SCLC and
47.61% for NSCLC. Two-year survival rates were 0% for
SCLC and 11.86% for NSCLC.

Mean DD level was 4110 ± 3732 ng/ml and median
value was 842 ± 3121 ng/ml. DD level was significantly
higher in late stage disease (Table 3).

Mean survival time was 14.35 ± 2.53 months and
median survival time was 13.77 ± 1.32 months in SqCLC
cases; mean survival time was 10.28 ± 1.66 months and
median survival time was 10.15 ± 1.34 months in
adenocarcinoma cases; mean survival time was 9.8 ±
7.63 months in ULC cases; mean survival time was 10.28
± 1.66 months and median survival time was 9.30 ±
3.18 months in NSCLC-U cases (Figure 1).

DD level was less than 500 ng/dl in 4.3% of the
patients, between 500 and 1000 ng/dl in 5.7%, and
≥1000 ng/dl in 94.3%. Survival analysis could not be
performed between normal and high level patients since
none of our patients had a normal DD level (<400 ng/dl).
Median survival time was 5.60 ± 2.45 months and
12.6 ± 0.61 months in patients with a DD level greater
and less than 2850 ng/dl, respectively ( P = 0.002).

Significant difference was detected between all NSCLC
and SCLC cases in terms of survival time ( P < 0.005).
Survival times of SqCLC cases were significantly different
compared to adenocarcinoma cases ( P < 0.01) and
NSCLC-I cases ( P < 0.05). No significant difference was
found between NSCLC and adenocarcinoma cases in
terms of survival time ( P < 0.05).

DD levels were significantly higher in SCLC cases
compared to NSCLC cases (Figures 3 and 4) ( P = 0.024).
No significant difference was found between SCLC cases
and ULC cases (Figure 3).

1.2
Histopathology
1.0

Undifferentiated

Oum Survival

.8
Adenocarcinoma
.6
.4

NSCLC-I

.2

SqCLC

0.0
-.2
-10
0
10
SURVIVAL (MONTHS) P = 0.0001

SCLC
20

30

40

Figure 1. Survival times for different histopathological subgroups (SCLC: Small Cell Lung
Cancer, NSCLC-I: Non-Small Cell Lung Cancer-undifferentiated, SqCLC: Squamous Cell
Lung Cancer, ULC: Undifferentiated Lung Cancer).
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Table 2. Demographic and histopathological characteristics of the patients according to stage of
disease.
Characteristic

Stage I-II-IIIA
(n)

%

Stage IIIB-IV
(n)

%

<65 years

6

100

35

54.6

≥65 years

0

0

29

45.4

Male

6

100

59

92.1

Female

0

0

5

7.9

SCLC

0/0*

0

7/7**

100

SqCLC

2/16

12.5

14/16

87.5

NSCLC-I

1/14

7.1

13/14

92.8

Adenocarcinoma

3/30

10

27/30

90

ULC

0/0

0

2/2

100

Age

Sex

Histopathology

Abbreviations: SCLC: Small Cell Lung Cancer, NSCLC-I: Non-Small Cell Lung Cancerundifferentiated, SqCLC: Squamous Cell Lung Cancer, ULC: Undifferentiated Lung Cancer.
*Limited disease; **Extensive disease

1.2
1.0

Oum Survival

.8
.6
.4

STAGE
Late
stage

.2
0.0

Early
stage

-.2
-10
0
SURVIVAL (months)

10

20

30

40

Figure 2. Comparison of survival time in early and late stage disease.

No significant difference was found in DD levels of
NSCLC subgroups except ULC cases in which DD levels
were significantly higher ( P = 0.002).
Compared to early stage cases, DD level was
significant different in late stage cases ( P = 0.025)
(Figure 5).

DD levels were significantly correlated with survival (
P = 0.012) and histopathological type ( P = 0.002).
High levels of DD was found to be an independent risk
factor in monovariate regression analysis (RR = 1, 95%
CI 1-1, P = 0.013) and in multivariate regression
analyses (RR = 1, 95% CI 1-1, P = 0.014).
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Table 3. Comparison of DD levels between early and late stage disease and patients with or
without thromboembolism.
DD (ng/gl)

P value

Early stage (I,II,IIIa) Median ± SD

3957 ± 2942 (982-8114)

0.025

Late stage (IVa) Median ± SD

4125 ± 3165 (302-11442)

Thromboembolism present

5676 ± 2791

Thromboembolism absent

3936 ± 3133

0.162

12000

14000

10000

12000

8000

10000
DD (ng/ml)

DD (ng/ml)

14000

6000
4000
2000

2000
7
SCLC

14

21
28
35
NSCLC-I
UNDIFFERENTIATED
SqCLC
ADENOCARCINOMA

HISTOPATHOLOGY
Figure 3. Comparison of DD levels in different histopathological
subgroups (P = 0.002).

12000
DD (ng/ml)

10000

-2000
N-

7
SCLC

21
NSCLC-I

Figure 4. Comparison of DD levels in SCLC and NSCLC cases (P =
0.024).

Portal thrombosis was detected in the follow-up
abdominal computerized tomography of an asymptomatic
patient. All thromboembolic events have been discovered
after treatment of the patients and not in the early period
of diagnosis.

8000
6000
4000
2000
0
G
Earl Stage

G+
Late Stage

Figure 5. Comparison of DD levels in early and late stage disease (P =
0.025).

A total of 7 (10%) thromboembolic events were
noted in our study: 2 femoral artery thromboses, 1 portal
vein thrombosis, 1 brachiocephalic vein thromboses, and
3 pulmonary emboli. According to histopathological
types, 5 of these events were in adenocarcinoma cases, 1
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0

in SCLC cases and 1 in SqCLC cases. Venous Doppler
Ultrasonography study for the detection DVT was done in
2 pulmonary emboli cases and revealed normal findings.

14000

-2000
N-

6000
4000

0
-2000
-12

8000

While platelet counts were within normal limits in
patients with arterial thrombus, they were increased over
normal limits in patients with portal and brachiocephalic
vein thrombus. Platelet counts were at lower and upper
limits of normal in patients with pulmonary emboli.
Among the patients in whom thromboembolic events
have occurred, 5 of them (71.4%) had received
chemotherapy, 2 of them (28.6%) (femoral artery
thrombus, pulmonary emboli) had received both
chemotherapy and radiotherapy. None of the patients, in
whom thromboembolic events have occurred, had
surgical treatment.
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Figure 6. Comparison of survival time in cases with and without thromboembolism.

Median survival time was 9.40 ± 3.65 months in
patients with thromboembolic events, and 11.77 ± 1.10
months in patients without a thromboembolic event, and
this difference was statistically significant ( P = 0.042)
(Figure 6).
Thromboembolism was found to be an independent
risk factor for decreased survival in monovariate
regression analysis (RR = 0.289, 95% CI 0.122-0.685,
P = 0.005) and multivariate regression analyses (RR =
2.446, 95% CI 0.945-6.33, P = 0.065).
Comparison of DD levels between patients with or
without thromboembolism is shown at Table 3.
Discussion
In lung cancer, exhibiting an increasing incidence in
recent years, thromboembolic events are the leading
cause of cancer-related deaths in this patient population.
Despite advances in treatment approaches, no significant
increase in survival rates or improvement in patients’
quality of life is observed.
Determining the high-risk patient groups early and
classification of patients accordingly may help tailoring
treatment modifications. More aggressive treatment
methods can be implemented in early stage patients who
demonstrate a hypercoagulative state. Application of
palliative treatments instead of chemotherapy in late
stage disease may reduce drug-related costs and improve
patient comfort.

Coagulation and fibrinolytic system constitutes an
important component of the prognosis of lung cancer.
This system plays significant roles in various processes
from the early period of tumor formation until the
patient’s death (1). Even though it may not be clinically
manifest in most cancer cases, subclinical coagulation
system activation is often present and this phenomenon
can be demonstrated by various markers (4,5).
Measurement of DD levels can be sufficient to detect
coagulation and fibrinolytic system activation. In the light
of the above-mentioned features, DD levels might be used
as a beneficial test in defining present disease status,
planning further investigations, and selecting proper
treatment. Similar approach can also be applied to other
malignant disorders.
The relationship between cancer and the coagulation
system has first been described by Trousseau. Trousseau
has explained this phenomenon in 1865; shortly before
he was diagnosed with gastric cancer. One out of 7
patients hospitalized with the diagnosis of cancer dies due
to pulmonary emboli. There is localized cancer and/or
limited metastasis in 60% of these patients. Frequency of
thromboembolic events in lung cancer patients varies
between 6% and 8%. Still, true rates for
thromboembolic events are unknown owing to lack of
information in clinical trials and difficulties in performing
full diagnostic work-up in every patient (11).
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Trousseau has demonstrated that systemic activation
of coagulation and fibrinolytic system is involved in
almost every cancer case. He has stated that prothrombin
time (PT) and activated partial thromboplastin time
(aPTT) may be prolonged or reduced, and that there is an
increase in thrombin production markers such as
activated coagulation factors (e.g. fibrinogen, TAT, or F
1+2). Later on, clinical (evident by thromboembolic
events) or subclinical activation of coagulation and
fibrinolytic system has been demonstrated in numerous
studies conducted in different cancer types. It has been
established in these studies that survival rate is worse in
these patients and activation of the coagulation and
fibrinolytic system significantly contributes to tumor
spread through various mechanisms.
The relationship between coagulation and fibrinolytic
system markers and survival has also been investigated.
Activation of the coagulation and fibrinolytic system in
cancer patients can be assessed by the measurement of
DD levels. High DD levels are found to be correlated with
late stage disease and short survival. DD levels show an
increase following chemotherapy and surgery. Although
diverse results have been obtained in various studies
performed in lung cancer subgroups, DD level correlation
with poor outcome is more marked in adenocarcinoma
(9,12). Hypercoagulability and fibrinolytic system
markers are directly correlated with tumor stage and
high levels of tumor markers (2). DD levels tend to rise
in several tumor types including lung cancers (1). Survival
rates are relatively poor in patients with high DD levels
(12).This relationship is more pronounced especially in
adenocarcinoma cases. Compared to early stage (stage I,
II, III) disease, DD levels are significantly higher in late
stage (stage IV) disease (10,13). Similarly, there was a
significant difference between Stage IIIB and IV patients
in our study.
In our study, mean and median DD level was 4110 ±
3732 ng/ml and 842 ± 3121 ng/ml, respectively. It was
less than 500 ng/ml in only 4.3%, between 500 and
1000 ng/dl in 5.7%, and greater than or equal to 1000
ng/dl in 94.3% of our patients.
Tagucci et al. have examined their cases in 2
categories: those with DD levels less than 150 ng/ml and
those with DD levels greater than or equal to 150 ng/ml
(13). However, DD level was found to be greater than
150 ng/dl in all of our lung cancers cases.
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High DD levels have previously been correlated with
late stage disease and short survival (9). In our study, DD
levels were correlated with survival ( P = 0.012) and
histopathological type ( P = 0.002) as well.
Unsal et al. have reported that mean survival time was
154 days (95% CI: 122-188 days) in patients with high
DD levels, and 308 days (95% CI: 227-409 days) in cases
with low DD levels ( P < 0.01) (10). In our study, median
survival time was 5.60 ± 2.45 months in patients with
DD levels greater than 2850 ng/dl, and 12.6 ± 0.61
months in patients with DD levels less than 2850 ng/dl (
P = 0.002). Thus, high DD levels were associated with a
significantly shorter survival time. High DD levels were
determined to be an independent risk factor in both
monovariate ( P = 0.013) and multivariate ( P = 0.014)
regression analyses.
Incidence of thromboembolic events in lung cancer
patients varies between 6% and 8% (11).
Thromboembolic events have been detected in 7 (10%)
of our patients. Median survival time was 9.40 ± 3.65
months and 11.77 ± 1.10 months in patients with and
without thromboembolism, respectively. The difference
between these groups was statistically significant ( P =
0.042). Thromboembolism has been found to be an
independent risk factor for shorter survival in both
monovariate ( P = 0.005) and multivariate regression ( P
= 0.065) analyses.
Incidence of thromboembolic events was noted as
10% in this study, whereas it has was reported between
6% and 8% worldwide (11). This figure may be lower
than expected since thromboembolic events are
frequently missed and underdiagnosed in patients with
malignancies. Especially, signs of pulmonary embolism
may be difficult to differentiate from the symptoms of
lung cancer. Mortality and morbidity may significantly be
reduced by monitorisation of coagulation markers and
administration of low molecular weight heparin in the
early disease period.
In conclusion, there are many prognostic factors in
lung cancer patients. Coagulation and fibrinolytic system
activation have an important role among these factors.
Survival was shorter in cases with coagulation/fibrinolytic
system activation even if this phenomenon may not be
clinically evident. Survival is substantially shortened in
cases with thromboembolic complications. Mortality and
morbidity may significantly be reduced by early detection
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of coagulation markers and administration of low
molecular weight heparin in these patients.
DD levels were significantly high and correlated with
short survival in our lung cancer patients. DD levels were
higher than 500 ng/dl in 95.7% of the cases. Significant
difference was noted in SCLC cases of late stage and
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extensive disease. DD level has been determined as an
independent risk factor for increased mortality in lung
cancer patients. DD level can be used as an inexpensive
screening tool in lung cancer patients in order to
determine the high risk patients for thromboembolic
event and initiate early treatment modalities.
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